332 related articles for article (PubMed ID: 36576563)
21. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
22. Delayed euDKA Associated With Dapagliflozin After Pancreatitis.
Wu G; Wu S; Tang J; Wu H
Clin Ther; 2023 Jul; 45(7):e167-e170. PubMed ID: 37248092
[TBL] [Abstract][Full Text] [Related]
23. Euglycemic Diabetic Ketoacidosis: Hidden in Plain Sight.
Crespo L; McConnell B; Wick JY
Consult Pharm; 2016; 31(8):426-34. PubMed ID: 27535077
[TBL] [Abstract][Full Text] [Related]
24. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
26. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
[TBL] [Abstract][Full Text] [Related]
27. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
[TBL] [Abstract][Full Text] [Related]
28. Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database.
Zhang L; Mao W; Li X; Wang X; Liu J; Hu S; Hu J
Front Pharmacol; 2022; 13():977582. PubMed ID: 36467046
[No Abstract] [Full Text] [Related]
29. Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.
Patil T; Cook M; Hobson J; Kaur A; Lee A
Am J Cardiol; 2023 Aug; 201():281-293. PubMed ID: 37393731
[TBL] [Abstract][Full Text] [Related]
30. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Ahmed M; McKenna MJ; Crowley RK
Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Fadini GP; Bonora BM; Avogaro A
Diabetologia; 2017 Aug; 60(8):1385-1389. PubMed ID: 28500396
[TBL] [Abstract][Full Text] [Related]
32. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
33. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
34. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
Puls HA; Haas NL; Franklin BJ; Theyyunni N; Harvey CE
Am J Emerg Med; 2021 Jun; 44():11-13. PubMed ID: 33571749
[TBL] [Abstract][Full Text] [Related]
35. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
[TBL] [Abstract][Full Text] [Related]
36. Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
Haddadin R; Aboujamra D; Iraninezhad H
Cureus; 2023 Dec; 15(12):e51184. PubMed ID: 38283482
[TBL] [Abstract][Full Text] [Related]
37. Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events.
Alkabbani W; Pelletier R; Gamble JM
Am J Epidemiol; 2021 Aug; 190(8):1572-1581. PubMed ID: 33751032
[TBL] [Abstract][Full Text] [Related]
38. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
40. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy.
Smith A; Holtrop J; Sadoun M
Cureus; 2021 Apr; 13(4):e14297. PubMed ID: 33968511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]